$ARDX News

Ardelyx: Low Price, But High Implied Valuation

Ardelyx Presents Data Analysis Evaluating Long-Term Impact Of XPHOZAH On Serum Electrolytes And Selected Nutrition Biomarkers At The National Kidney Foundation Meetings

Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript

Ardelyx Inc (NASDAQ:ARDX) Reports Strong Q1 Revenue Beat as IBSRELA Momentum Accelerates

Ardelyx Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $94.473M Beat $92.655M Estimate

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Ardelyx Data From IBS-C Clinical Development Program Demonstrates Tenapanor Offers Rapid, Sustained Relief For Adults With IBS-C

Is Ardelyx (ARDX) Pricing In Its Potential After Recent Share Price Weakness

Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Ardelyx And LGPA Announce Multi-Year Partnership To Support Women's Digestive Health

Ardelyx (ARDX) Valuation Check After 2025 Results And Strong 2026 Growth Guidance

Wedbush Reiterates Outperform on Ardelyx, Maintains $19 Price Target

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Ardelyx, Inc. 2025 Q4 - Results - Earnings Call Presentation

Ardelyx, Inc. Q4 2025 Earnings Call Summary

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Breaking Down Ardelyx: 7 Analysts Share Their Views